Moreover, molecularly targeted therapies against PI3K and the TGF-β axis may be candidates for treatment of advanced GSC, although therapeutic strategies for targeting mutations in PTEN and SMAD4 have not been established for gastric cancer. Here, SMAD4 is linked to gastric cancer.